To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

PresentationOperator Good morning. My name is Jenny, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics' call to discuss top line results from the Phase III SENTRY trial. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company's request. I would now like to turn the conference call over to Brendan Strong, Senior Vice President, Investor Relations. ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares are down on Tuesday as the company reported mixed results from its Phase 3 SENTRY trial for myelofibrosis.Myelofibrosis is a rare, chronic blood cancer (myeloproliferative neoplasm) where bone marrow is replaced by scar tissue, disrupting blood cell production.Trial Shows Strong Spleen Reduction But Misses Symptom EndpointThe SENTRY trial met its first co-primary endpoint, showing significant improvement in spleen volume reduction for patients treated with s ...

Karyopharm Therapeutics (NasdaqGS:KPTI) Update / briefing March 24, 2026 08:00 AM ET Company ParticipantsBrendan Strong - SVP of Investor Relations and Corporate CommunicationsBrian Abrahams - Managing Director and Global Head of Healthcare ResearchJohn Mascarenhas - Investigator, Consultant and Advisory Board MemberReshma Rangwala - Chief Medical Officer and Head of ResearchRichard Paulson - President and CEOConference Call ParticipantsColleen Kusy - Senior Research AnalystEdward Tenthoff - Managing Direct ...

Brendan Strong, SVP, Investor Relations Opening Remarks Richard Paulson, President and Chief Executive Officer Phase 3 SENTRY Topline Results March 24, 2026 On Today's Call Welcome Phase 3 SENTRY Topline Results Dr. Reshma Rangwala, Chief Medical Officer and Head of Research Myelofibrosis Treatment Landscape Dr. John Mascarenhas, Principal Investigator of Phase 3 SENTRY Trial; Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of the Center of Excellence for Blood Cancers and ...

Karyopharm Therapeutics Inc. (KPTI) on Tuesday reported positive topline results from its Phase 3 SENTRY trial of selinexor in combination with ruxolitinib in frontline myelofibrosis. Karyopharm shares were up more than 15% in pre-market trading.The trial met its first co-primary endpoint, showing a statistically significant improvement in spleen volume reduction of at least 35% (SVR35) in patients treated with the combination compared with ruxolitinib alone.At week 24, 50% of patients receiving the seline ...

Skip to main content Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Follow Incyte Corp Our Standards: The Thomson Reuters Trust Principles., opens new tab Purchase Licensing Rights Business Follow March 24 (Reuters) - Karyopharm Therapeutics (KPTI.O), opens new tabsaid on Tuesday its oncology therapy showed a statistically significant improvement in spleen volume in a lat ...

Karyopharm Announces $30 Million Private Placement with RA Capital Accessibility StatementSkip Navigation NEWTON, Mass., March 24, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement with RA Capital Management for a private placement that is expected to result in gross proceeds of approximately $30 million before deducting placement agent fees an ...

– While Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline, SENTRY Did Not Meet its Second Co-Primary Endpoint of Abs-TSS – – SENTRY Demonstrated a Rapid and Near Doubling of Patients Achieving SVR35 at Week 24, versus Ruxolitinib – – Promising Overall Survival Signal with >50% Reduction of Risk of Death versus Ruxolitinib – – Evidence of Potential Disease Modification with More Patients Achieving 20% Reductions in VAF as Early as Week 24 versus Ruxolitinib – – No New Safety S ...

Core Viewpoint - Karyopharm Therapeutics (KPTI) has shown a significant price increase of 58% over the past four weeks, with a mean price target of $14.67 indicating a potential upside of 56.1% from the current price of $9.4 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $5.32, where the lowest estimate is $6.00 (indicating a 36.2% decline) and the highest is $21.00 (indicating a 123.4% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about KPTI's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price movements [11] - Over the last 30 days, two estimates have been revised upward, leading to a 13.3% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - KPTI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside in the near term [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does suggest a positive direction for price movement [14]